Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04586478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 30, 2024 to Mar 30, 2024v9
  2. Primary completion date: Jun 30, 2024 to Dec 30, 2024v8
  3. Primary completion date: Dec 30, 2023 to Jun 30, 2024v7
  4. Enrollment target: 36 to 60
    • Study sites: 18 to 17
    • Eligibility criteria shortened, about 92 words
    • Secondary endpoints revised (9)
    v6
  5. Primary completion date: Dec 30, 2022 to Dec 30, 2023
    • Study completion date: Mar 31, 2023 to Sep 30, 2025
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Jun 30, 2021 to Dec 30, 2022v4
  2. Site details revised at 11 of 18 sitesv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 9, 2020 to Oct 26, 2020
    • Site details revised at 18 of 18 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.
Trial Details
NCT Number NCT04586478
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions
(from sponsor)		 Non-Hodgkin's Lymphoma
Related terms Lymphoma, Non-Hodgkin
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov